Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfa-2a in Resected HCC
NCT03253250Phase 4Unknown
- Sponsor
- Huashan Hospital
- Start
- Sep 2017
- Primary completion
- Jun 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a in hepatocellular carcinoma (HCC), sponsored by Huashan Hospital. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03253250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253250.